All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
The anti-CD19 chimeric antigen receptor (CAR) THP1 cell line is a stable cell line developed using anti-CD19 CAR lentivirus transfection. This transfected CAR lentiviral vector is constructed to express a scfv of anti-CD19 antibody (FMC63) linked to CD3ζ signaling domains.The anti-CD19 CAR engineered THP1 cells can be used to be differentiated into macrophage cells for in vitro or in vivo phagocytosis studies. This CAR-THP1 cell line product can be used for the researches of B cell lymphomas, acute lymphoblastic leukemia (ALL), and chronic lymphocytic leukemia (CLL).
There are currently no customer reviews or questions for Anti-CD19 (FMC63) ICD(CD3ζ) CAR THP1 Cell Line (CARTHP-W0033). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION